The Australian advantage

Fast and pragmatic regulatory environment for Phase 1 clinical studies

• 4-6 weeks for review and approval for healthy volunteer studies
• IND not required to conduct clinical trials in Australia

R&D Tax Incentive

• Up to $0.435 returned for every $1.00 spent

Quality

• Australia follows ICH guidelines so data is accepted by global regulatory bodies

Added benefits

Many of our clients submit an IND for review and complete a Phase 1 clinical trial in Australia during the IND review process.

• Highly experienced, Phase 1 and hospital based state-of-the-art units
• High certainty of getting regulatory approval for conducting studies in heathy volunteers
• History of successful FDA and other regulatory agency inspections
• Access to diverse population